PYXS — Pyxis Oncology, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1782223 ·
Last close
$1.44
Market Cap
$172.24M
52W High
$5.55
52W Low
$1.03
ADV30
837,799
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -25,990,000 -25,346,000 54,922,000 18,855,000 43,482,000
Mar 2026 0 — -24,360,000 -23,272,000 64,300,000 5,766,000 33,032,000
Dec 2025 11,038,000 8,650,000 -18,295,000 -18,106,000 91,520,000 15,422,000 38,112,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-67,910,000
Investing CF
$65,402,000
Financing CF
$10,630,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.36
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-491,795,000
Inventory
—
Receivables
$700,000
ST Investments
$14,141,000
EBIT TTM
$-92,106,000
Pretax Income TTM
$-87,624,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$11,038,000
EBITDA
$-85,526,000
Free Cash Flow
$-23,186,750
Enterprise Value
$119,122,960
Total Cash
$32,996,000
Total Debt
$17,832,000
Shares Out
119,607,855
Trailing EPS
$-1.27
Book Value
$0.85
ROE
-179.1%
ROA
-63.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 13,858,000 -84,420,000 -79,621,000 91,520,000 38,112,000 53,408,000 -63,502,000
Dec 2024 16,146,000 -68,496,000 -77,331,000 157,181,000 36,430,000 120,751,000 -57,672,000
Dec 2023 0 -82,196,000 -73,790,000 173,726,000 48,022,000 125,704,000 -70,709,000
Dec 2022 0 -123,481,000 -120,717,000 211,379,000 50,555,000 160,824,000 -89,335,000

TTM Snapshot

Revenues TTM
$6,662,000
NetIncome TTM
$-88,727,000
OpCashFlow TTM
—
Assets (Latest)
$54,922,000
Forward EPS
$-0.88

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.41 · call volume: 22 · put volume: 50

Peers — same industry

TickerNameMarket CapLastDaily %
SLGL Sol-Gel Technologies Ltd. $172.97M $52.83 —
IFRX InflaRx N.V. $169.47M $1.15 —
KRRO Korro Bio, Inc. $169.10M $12.32 —
ORMP ORAMED PHARMACEUTICALS INC. $168.29M $3.87 —
ELDN Eledon Pharmaceuticals, Inc. $167.23M $1.98 —

News headlines (Yahoo Finance, 1h cache)

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
2026-11-18 23:01 · Yahoo
Pyxis Oncology Catalysts on Track With Upcoming Trial Results in Head, Neck Cancer Treatment, RBC Says
2026-11-06 16:33 · Yahoo
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
2026-11-05 12:00 · Yahoo
Pyxis Oncology to Participate in Upcoming Investor Conferences
2026-10-28 11:30 · Yahoo
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Ca
2026-10-27 12:45 · Yahoo
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
2026-10-02 11:00 · Yahoo
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
2026-09-30 05:11 · Yahoo
Pyxis Oncology Announces Proposed Public Offering
2026-09-29 20:24 · Yahoo
Pyxis Oncology shares fall 7% despite updated MICVO trial results
2026-09-09 14:08 · Yahoo
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+
2026-09-09 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.